

Public Assessment Report

Name of the Product:

Aprepitant Sandoz

80 mg, 125 mg, 125 mg + 80 mg hard capsules

(aprepitant)

Procedure number: HU/H/0498/001-003/DC

Marketing authorisation holder: Sandoz Hungária Kft.

Date: 21 April 2020

CONTENT

LAY SUMMARY	3
SCIENTIFIC DISCUSSION during the initial phase	8
I. Introduction	9
II. Quality aspects	
II.1 Introduction	10
II.2. Drug substance	10
II.3 Medicinal product	11
II.4 Discussion on chemical, pharmaceutical and biological aspects	12
III. Non-clinical aspects	
III.1 Introduction	13
III.2 Pharmacology	13
III.3 Pharmacokinetics	13
III.4 Toxicology	13
III.5 Ecotoxicity/environmental risk assessment	13
III.6 Discussion on the non-clinical aspects	13
IV. Clinical aspects	
IV.1 Introduction	15
IV.2 Pharmacokinetics	
IV.2.1 Literature data	15
IV.2.2 Bioequivalence studies	16
IV.3 Pharmacodynamics	19
IV.4 Clinical efficacy	19
IV.5 Clinical safety	19
IV.6 Pharmacovigilance	
IV.6.1 Summary of the Pharmacovigilance System	19
IV.6.2 Risk Management Plan	19
IV.6.3 Periodic Safety Update Reports	20
IV.7 Discussion on clinical aspects	20
V. Overall conclusion, benefit/risk assessment and recommendation	
V.1 Summary	21
V.2 Classification	21
V.3 Package leaflet and user consultation	21

UPGRADE: STEPS TAKEN AFTER THE INITIAL PROCEDURE WITH AN INFLUENCE
ON THE PUBLIC ASSESSMENT REPORT

LAY SUMMARY

After careful assessment of its quality and therapeutic benefit/risk ratio, the member states have granted the marketing authorisation of the Aprepitant Sandoz 80 mg, 125 mg and 125 mg + 80 mg hard capsules. The holder of the marketing authorisation in the Reference Member State is Sandoz Hungária Kft.

The active substance is aprepitant. Each hard capsule contains 80 mg or 125 mg of aprepitant.

The other ingredients are: sucrose, cellulose microcrystalline sphere 500 (E 460), hydroxypropylcellulose (HPC-SL, E 463), sodium laurilsulfate, gelatine, titanium dioxide (E 171); the 125 mg hard capsule also contains red iron oxide (E 172).

The 80 mg hard capsules are opaque with a white body and cap, containing white to off-white pellets.

The 125 mg hard capsules are opaque with a white body and pink cup, containing white to off-white pellets.

The capsules are supplied in Aluminium-OPA/Alu/PVC blister.

The 3-day treatment pack contains one blister of 125 mg capsules and one blister of 80 mg capsules.

Aprepitant Sandoz hard capsules (further on: Aprepitant Sandoz) contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". The brain has a specific area that controls nausea and vomiting. Aprepitant works by blocking signals to that area, thereby reducing nausea and vomiting. Aprepitant Sandoz is used in adults and adolescents from the age of 12 years in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that are strong and moderate triggers of nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin or epirubicin).

What patients (or parents) need to know before taking (giving) Aprepitant Sandoz?

Those who

- (or whose child) is allergic to aprepitant or any of the other ingredients of this medicine,
- are taking a medicine containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems)

must not take Aprepitant Sandoz.

If the patient (child) is taking these medicines, the doctor must be consulted since the treatment must be modified before taking Aprepitant Sandoz.

Warnings and precautions

Before treatment with Aprepitant Sandoz, the doctor must be consulted if the patient has liver disease because the liver is important in breaking down the medicine in the body. The doctor may therefore have to monitor the condition of patient's liver.

Children and adolescents

The 80 mg and 125 mg strengths of Aprepitant Sandoz must not be given to children under 12 years of age, because these doses have not been studied in this population.

Other medicines and Aprepitant Sandoz

Aprepitant Sandoz can affect other medicines both during and after treatment with aprepitant, its active substance. There are some medicines that should not be taken with Aprepitant Sandoz (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment.

The effects of Aprepitant Sandoz or other medicines might be influenced if the patient takes it together with other medicines including those listed below. Patients should consult their doctor if taking any of the following medicines:

- birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with Aprepitant Sandoz. Another or additional non-hormonal form of birth control should be used during treatment with Aprepitant Sandoz and for up to 2 months after using it,
- cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants),
- alfentanil, fentanyl (used to treat pain),
- quinidine (used to treat an irregular heartbeat),
- irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
- medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines),
- warfarin, acenocoumarol (blood thinners; blood tests may be required),
- rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),
- phenytoin (a medicine used to treat seizures),
- carbamazepine (used to treat depression and epilepsy),
- midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep),
- St. John's Wort (an herbal preparation used to treat depression),
- protease inhibitors (used to treat HIV infections)
- ketoconazole except shampoo (used to treat Cushing's syndrome - when the body produces an excess of cortisol),
- itraconazole, voriconazole, posaconazole (antifungals),
- nefazodone (used to treat depression),
- corticosteroids (such as dexamethasone and methylprednisolone),
- anti-anxiety medicines (such as alprazolam),
- tolbutamide (a medicine used to treat diabetes)

The doctor should also be consulted if the patient (a child) is taking, have recently taken, or might take any other medicines.

Pregnancy and breast-feeding

This medicine should not be used during pregnancy unless clearly necessary. Those who are pregnant or breast-feeding, think they may be pregnant or are planning to have a baby, ask their doctor for advice before taking this medicine.

For information regarding birth control, see ‘Other medicines and Aprepitant Sandoz’.

It is not known whether Aprepitant Sandoz is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. It is important to tell the doctor if the patient is breast-feeding or is planning to breast-feed before taking this medicine.

Driving and using machines

It should be taken into account that some people feel dizzy and sleepy after taking Aprepitant Sandoz.

If the patient feels dizzy or sleepy, avoid driving, riding a bicycle or using machines or tools after taking Aprepitant Sandoz (see ‘Possible side effects’).

Aprepitant Sandoz contains sucrose

Aprepitant Sandoz capsules contain sucrose. Those who (or whose child) have been told by their doctor that they have an intolerance to some sugars, contact the doctor before taking this medicine.

How to take Aprepitant Sandoz

Patients should always take this medicine or give this medicine to the child exactly as the doctor, pharmacist or nurse has told them. They should check with the doctor, pharmacist or nurse if they are not sure. Aprepitant Sandoz should always be taken together with other medicines, to prevent nausea and vomiting. After treatment with Aprepitant Sandoz, the doctor may ask the patient to continue taking other medicines including a corticosteroid (such as dexamethasone) and a ‘5HT₃ antagonist’ (such as ondansetron) for preventing nausea and vomiting.

The recommended oral dose of Aprepitant Sandoz is as follows: on day 1: one Aprepitant Sandoz 125 mg capsule 1 hour before starting the chemotherapy session and on days 2 and 3: one Aprepitant Sandoz 80 mg capsule each day.

If no chemotherapy is given, Aprepitant Sandoz should be taken in the morning. If chemotherapy is given, it should be taken 1 hour before starting the chemotherapy session.

Aprepitant Sandoz can be taken with or without food. The capsule should be swallowed whole with some liquid.

What to do if more Aprepitant Sandoz has been taken than it should have been?

Patients must not take more Aprepitant Sandoz than the doctor recommends. If somebody has taken too many capsules, the doctor must be contacted immediately.

What to do if taking Aprepitant Sandoz has been forgotten?

When a dose has been missed, the doctor must be contacted for advice.

Possible side effects

Like all medicines, Aprepitant Sandoz can cause side effects, although not everybody experiences them.

Patients (children) must stop taking Aprepitant Sandoz and see a doctor immediately if noticing any of the following side effects, which may be serious, and for which urgent medical treatment may be needed: hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be estimated from the available data); these are signs of an allergic reaction.

Other side effects that have been reported are listed below.

Common side effects (may affect up to 1 in 10 people):

- constipation, indigestion,
- headache,
- tiredness,
- loss of appetite,
- hiccups,
- increased amount of liver enzymes in the blood.

Uncommon side effects (may affect up to 1 in 100 people):

- dizziness, sleepiness,
- acne, rash,
- anxiousness,
- burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,
- increased painful or burning urination,
- weakness, generally feeling unwell,
- hot flush/reddening of the face or skin,
- fast or irregular heartbeats,
- fever with increased risk of infection, lowering of red blood cells.

Rare side effects (may affect up to 1 in 1,000 people):

- difficulty thinking, lack of energy, taste disturbance,
- sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash, Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction),
- euphoria (feeling of extreme happiness), disorientation,
- bacterial infection, fungal infection,
- severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating,
- frequent urination, passing more urine than normal, presence of sugar or blood in urine,
- chest discomfort, swelling, change in the manner of walking,

- cough, mucus in the back of the throat, throat irritation, sneezing, sore throat,
- eye discharge and itching,
- ringing in the ear,
- muscle spasms, muscle weakness,
- excessive thirst,
- slow heartbeat, heart- and blood vessel disease,
- lowering of white blood cells, low sodium levels in the blood, weight loss.

How to store Aprepitant Sandoz

This medicine does not require any special storage conditions, but it must be kept out of the sight and reach of children.

The capsule should not be removed from its blister until the patient is ready to take it.

Scientific discussion

during the initial phase

This module reflects the scientific discussion for the approval of Aprepitant Sandoz 80 mg, 125 mg, 125 mg + 80 mg hard capsules. The procedure was finalised at 04 December 2017. For information on changes after this date please refer to the module 'Update'.

I. INTRODUCTION

In accordance to the Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 *on the Community code relating to medicinal products for human use*, an application has been submitted to the reference and competent authorities of the Member State concerned.

This Decentralised Procedure application (Reference member state, RMS: Hungary, concerned member states, CMS:

- procedure HU/H/0498/001/DC: Austria, Croatia, Denmark, France, Germany, the Netherlands, Romania, Slovenia, Sweden and the United Kingdom,
- procedure HU/H/0498/002/DC: Austria, Croatia, Denmark, Germany, the Netherlands, Romania, Slovenia, Sweden and the United Kingdom,
- procedure HU/H/0498/003/DC: Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, the Netherlands, Poland, Romania, Slovakia, Slovenia, Sweden and the United Kingdom

concerned generic versions of aprepitant 80 mg, 125 mg and co-packaged 125 mg + 80 mg hard capsules (Aprepitant Sandoz hard capsules, named Aprepitant Hexal in Germany).

The application has been filed pursuant to Article 10(1) of Directive 2001/83/EC and therefore contained no new clinical or preclinical data, other than supporting literature where necessary.

Based on the review of the quality, safety and efficacy data, the Member States have granted marketing authorisation for Aprepitant Sandoz 80 mg, 125 mg and 125 mg + 80 mg hard capsules (the marketing authorisation holder in the RMS is Sandoz Hungária Kft.).

The marketing authorisation has been granted pursuant to Article 10(1) of Directive 2001/83/EC. The applicant has adequately demonstrated bioequivalence between the products applied for and reference products.

The originator and reference product has been Emend[®] 80 mg & 125 mg hard capsules by Merck Sharp & Dohme Ltd. UK, authorised for marketing since 2003 throughout the European Union.

The products are indicated for prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.

A comprehensive description of the indications and posology is given in the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

This chemical-pharmaceutical assessment report concerns the application of Aprepitant Sandoz 80 mg, 125 mg hard capsules and Aprepitant Sandoz 125 mg + 80 mg hard capsules via a decentralized procedure according to Article 10(1) of Directive 2001/83/EC (i.e. a generic application).

The reference products are Emend 80 mg, 125 mg, 80 mg & 125 mg hard capsules, the original products of Merck Sharp & Dohme Ltd., UK.


II.2 Drug substance

Data on the quality and manufacture of the active substance were provided in the submission using Active Substance Master File (ASMF) procedure with additional data in the marketing authorisation dossier. The Quality Overall Summary is adequate.

INN name: aprepitant

Chemical name: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one

Structure:



The drug substance is white to cream-coloured crystalline powder, soluble in methanol, slightly soluble in acetonitrile, practically insoluble in water. It shows polymorphism, the manufacturers consistently produce the correct isomer and the same polymorphic form.

The ASMF holder presented complete details of the manufacturing process. Description of the manufacturing process of the drug substance is adequate.

Evidence of the structure has been confirmed by NMR, MS, FT-IR, XRDP, UV spectroscopy and elemental analysis. The impurity profile of the substance contains detailed information about genotoxic impurities, residual solvents and catalysts.

The substance is specified according to the requirements of the current Ph. Eur. monograph, additional specification has been set. for residual solvents, particle size distribution, polymorphism, impurities and microbial impurities.

The Ph. Eur. specification includes the following tests for aprepitant: appearance, solubility, identification by IR, specific optical rotation, water content, sulphated ash, related substances, enantiomeric purity and assay.

The presented specification is in accordance with the Ph. Eur. general monograph on *Substances for Pharmaceutical Use* and the International Council on Harmonisation (ICH) Q6A guideline. The specification reflects all relevant quality attributes of the active substance and was found to be adequate to control the quality of the drug substance. The limits set are properly justified.

Testing methods not described in detail in the pharmacopoeia are adequately drawn up and sufficiently validated. Reference materials used by the active substance manufacturer and the drug product manufacturer for the control of the substance are adequately characterised.

The substance complies with the requirements of the EMA guideline on genotoxic impurities.

Batch analysis data justify the limits, indicate the good performance of testing methods, and demonstrate the batch to batch consistency of the production.

Stability studies have been performed with the drug substance. According to the presented stability data the proposed re-test period is acceptable with the proposed storage condition.

Good Manufacturing Practice (GMP) compliance of the drug substance manufacture is demonstrated by the applicant.

II.3 Medicinal product

The aim was to develop hard capsules containing aprepitant as drug substance in 80 mg and 125 mg doses, pharmaceutically equivalent and bioequivalent to the reference medicinal product Emend 80 mg and 125 mg hard capsules, the branded original products of Merck Sharp & Dohme Ltd. UK.

A satisfactory package of data on development pharmaceuticals has been presented. Brief discussion on reasons for inclusion and quantity of excipients has been provided.

As regards dissolution and impurity profile the product is shown to be similar to the reference product.

The compositions and the pharmaceutical tests evaluated during development of the final formulation are included in the documentation. As a result of development studies product with the following appearance, composition and packaging was obtained:

- 80 mg: size 2, opaque hard gelatin capsule with a white body and cap containing white to off-white pellets.
- 125 mg: size 1, opaque hard gelatin capsule with a white body and pink cap containing white to off-white pellets.

The excipients used in the finished product are sucrose, microcrystalline cellulose (Spheres 500), hydroxypropylcellulose (HPC-SL), sodium laurilsulfate and capsule shell (titanium dioxide (E171), talc, red iron oxide (E172 only for 125 mg) and gelatine). All excipients used comply with their respective Ph. Eur. monograph. Compliance of the product with the general monograph of the Ph. Eur. *on the Products with the risk of TSE* has been demonstrated by the applicant.

A description and flow chart of the manufacturing method has been provided. Appropriate in-process controls are included in the manufacturing process. Satisfactory batch formulae were also presented. GMP compliance of the manufacturing site has been demonstrated.

The finished product specification is satisfactory. Acceptance criteria have been justified with respect to conventional pharmaceutical requirements as required in the relevant dosage form monograph of the Ph. Eur. and the ICH Q6A guideline. Appropriate control strategy was selected. The test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and complied with the specification. Certificates of analysis for the batches involved in the bioequivalence study are presented.

The container closure system of the product is OPA/Al/PVC//Al blister. Specifications and quality certificates for all packaging components are enclosed.

Finished product stability studies have been conducted in accordance with the current guidelines. Based on the results, a shelf-life of 2 years with no special storage conditions is approved.

The Summary of Product Characteristics, Package Leaflet and label texts are pharmaceutically acceptable.

II.4 Discussion on chemical, pharmaceutical and biological aspects

The product has been shown to meet the current regulatory requirements with regards to its quality and content of the active substance as well as dosage-form characteristics until the end of the approved shelf-life consistently. The manufacture and the quality standards applied adequately support the safe use and efficacy of the product.

From quality points of view the product is approvable.

III. NON-CLINICAL ASPECTS

III.1 Introduction

Pharmacodynamic, pharmacokinetic and toxicological properties of aprepitant are well known. As aprepitant is a widely used, well-known active substance, no further studies are required, and the applicant provided none. The non-clinical overview is therefore based on a review of data available in several scientific databases or published in relation to the active ingredient. For generic applications it is acceptable.

III.2 Pharmacology

Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors.

The active substance is a well-known compound. No further information was provided regarding the pharmacology of aprepitant.

III.3 Pharmacokinetics

No new non-clinical pharmacokinetic studies were conducted by the applicant.

III.4 Toxicology

No new toxicity studies were submitted by the applicant for the product, which is acceptable for this type of application.

III.5 Ecotoxicology/environmental risk assessment (ERA)

Since Aprepitant Sandoz is intended for generic substitution, this will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary.

III.6 Discussion on the non-clinical aspects

Abridged applications avoid the need for repetitive tests on animals. Pharmacodynamics, pharmacokinetics and toxicology of aprepitant are well-known. As Aprepitant Sandoz 80mg, 125 mg hard capsules is a generic product there is no need for further excessive non-clinical studies.

National Institute of Pharmacy
and Nutrition
Budapest, Hungary

Aprepitant Sandoz
80 mg, 125 mg, 125 mg + 80 mg hard capsules
HU/H/0498/001-003/DC
Public Assessment Report

The non-clinical part of the application is acceptable.

IV. CLINICAL ASPECTS

IV.1 Introduction

The clinical pharmacology of aprepitant is well known.

Except for demonstrating bioequivalence, no specific clinical studies have been performed, as the application is submitted in accordance with Article 10(1) of Directive 2001/83/EC as amended.

The application contains an adequate review of published clinical data.

IV.2 Pharmacokinetics

IV.2.1 Literature data

The mean absolute oral bioavailability of aprepitant is 67 % for the 80 mg capsule and 59 % for the 125 mg capsule. The mean peak plasma concentration (C_{max}) of aprepitant occurred at approximately 4 hours (t_{max}). Oral administration of the capsule with an approximately 800 Kcal standard breakfast resulted in an up to 40 % increase in AUC of aprepitant. This increase is not considered clinically relevant.

The pharmacokinetics of aprepitant is non-linear across the clinical dose range. In healthy young adults, the increase in AUC_{∞} was 26 % greater than dose proportional between 80 mg and 125 mg single doses administered in the fed state. Following oral administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 and 3, the AUC_{0-24} (mean \pm SD) was 19.6 ± 2.5 $\mu\text{g}\cdot\text{h}/\text{mL}$ and 21.2 ± 6.3 $\mu\text{g}\cdot\text{h}/\text{mL}$ on Days 1 and 3, respectively. C_{max} was 1.6 ± 0.36 $\mu\text{g}/\text{mL}$ and 1.4 ± 0.22 $\mu\text{g}/\text{mL}$ on Days 1 and 3, respectively.

Aprepitant is highly protein bound, with a mean of 97 %. The geometric mean apparent volume of distribution at steady state (V_{dss}) is approximately 66 L in humans.

Aprepitant undergoes extensive metabolism. In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [14C]-fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma. Twelve metabolites of aprepitant have been identified in human plasma. The metabolism of aprepitant occurs largely via oxidation at the morpholine ring and its side chains and the resultant metabolites were only weakly active. In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.

Aprepitant is not excreted unchanged in urine. Metabolites are excreted in urine and via biliary excretion in faeces. Following a single intravenously administered 100 mg dose of [¹⁴C]-fosaprepitant, a prodrug for aprepitant, to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.

The plasma clearance of aprepitant is dose-dependent, decreasing with increased dose and ranged from approximately 60 to 72 mL/min in the therapeutic dose range. The terminal half-life ranged from approximately 9 to 13 hours.

IV.2.2 Bioequivalence studies

One pilot and two pivotal bioequivalence studies (one in fasting, one in fed conditions) have been performed to support essential similarity between the test and the reference preparations in healthy adult subjects. The 125 mg strengths were used in each case. The reference product was Emend[®] 125 mg capsules manufactured by Merck Sharp & Dohme Ltd., Netherland.

By the Sponsor's statement the studies were conducted in compliance with the requirements of guideline on *Good Clinical Practice* ICH Topic E6 (R1) (CPMP/ICH/135/95), Guideline on *the investigation of bioequivalence* (CPMP/EWP/QWP/1401/98 Rev. 1/Corr**, January 2010) and ethical principles stated in the last revision of Declaration of Helsinki.

Pilot study

It was a randomized, open label, single dose, crossover bioequivalence study in healthy adult human subjects under fasting conditions. The subjects were administered two kinds of formulations of Test or the Reference products, one capsule each. The main objective of this study was to compare the rate and extent of absorption of aprepitant from the Test and Reference products and also to estimate intra-subject variability of the primary pharmacokinetic parameters (C_{max} and AUC_{0-t}).

The results of the pilot study were used to select the proper Test product and to plan the two pivotal studies.

Pivotal study under fasting conditions

It was a single-dose, randomized, open-label, crossover study in healthy adult male subjects under fasting condition. Its main objective was to compare the rate and extent of absorption of aprepitant of the Test and Reference products.

The following pharmacokinetic parameters were determined:

- primary: AUC_{0-t} , AUC_{0-inf} , C_{max} ,
- other: T_{max} , $t_{1/2}$, kel .

Statistical methods used in evaluations used were as follows:

- descriptive statistics of pharmacokinetic parameters: arithmetic mean, standard deviation, minimum, maximum, median, CV%, geometric LS (least squares) means for test (T) and reference (R) pharmacokinetic data;
- log-transformation of AUC and C_{max} data;
- calculation of 90% confidence intervals for the difference between the least square means for primary parameters at $\alpha = 0.05$ significance level,
- applying non-parametric analysis of T_{max} on untransformed data;
- descriptive statistics of safety data collected during the whole study period.

Bioequivalence criteria: the Test product can be considered bioequivalent to the Reference product when the ln-transformed Test/Reference least-squares mean ratios and their 90% confidence intervals of the AUC_{0-t} and C_{max} parameters fall entirely within the acceptance interval of 80.00 - 125.00% for aprepitant. This was demonstrated for Aprepitant Sandoz.

Summary of the results_

Pharmacokinetic parameter	Geometric Mean Ratio T/R	90% Confidence Intervals
AUC _{0-t}	99.88	90.76 – 109.92
C _{max}	100.18	91.96 – 109.13

Safety results: no death, serious or clinically significant adverse events occurred during the study.

On the basis of results of this bioequivalence study the single dose of the Test and Reference products are bioequivalent in healthy adult human subjects under fasting conditions.

Pivotal study under fed conditions

The design of this investigation was a pivotal, single-dose, randomized, open-label, crossover one in healthy adult male subjects under fed condition. The subjects were administered the Test or Reference products as a single oral dose of one capsule each 30 minutes after the start of the high-fat high-calorie breakfast with a glass of water at ambient temperature.

Main objective of this study was to compare the rate and extent of absorption of aprepitant of the Test and Reference products administered to healthy volunteers in a single dose, under fed conditions.

Pharmacokinetic parameters, statistical methods applied, and bioequivalence criteria were the same as in the previous pivotal study.

The results are shown in the Table below.

Pharmacokinetic parameter	Geometric Mean Ratio T/R	90% Confidence Intervals
AUC _{0-t}	101.30	97.03 – 105.77
C _{max}	101.56	94.81 – 108.79

Safety results: no death, serious or clinically significant or unexpected adverse events occurred during the study.

Results derived from analysis of log-transformed primary parameters (C_{max}, AUC_{0-t}) for aprepitant show that the Test/Reference ratios of least-squares mean values and their 90% confidence intervals are entirely included within the acceptance range of 80%-125%. Thus, results support the bioequivalence between the Test and Reference treatments.

Biowaiver

The applicant claimed for biowaiver for the dose strength of 80 mg hard capsules on the basis of general biowaiver requirements (CPMP/EWP/QWP/1401/98 Rev 1 Corr**), as follows:

- both strengths i.e. 80 and 125 mg of proposed pharmaceutical products are manufactured by the same manufacturer and using the same manufacturing process.
- The qualitative composition of the different strengths is the same.
- The compositions of the claimed two strengths are proportionally similar.
- *In vitro* dissolution data confirm the *in vivo* similarity between the claimed strengths.
- Aprepitant exhibits non-linear (more than proportional) pharmacokinetics in the therapeutic range of 80-125 mg.

All criteria of general biowaiver claim were satisfied for the claimed dose strength (80 mg) according to the bioequivalence guideline in force (CPMP/EWP/1401/98 Rev.1 Corr** and EMA/CHMP/600958/2010/Corr.*). Similarity of dissolution profiles of the 80 and 125 mg dose strengths could be justified in accordance to the above bioequivalence guideline. Thus, the biowaiver claim for the 80 mg dose strength is justified.

Conclusion on bioequivalence studies

On the basis of results of the bioequivalence studies the single doses of the applicant's Aprepitant Sandoz 125 mg hard capsules and EMEND® 125 mg capsules (Merck Sharp & Dohme Ltd.) are considered bioequivalent in healthy adult human subjects under fast- and fed conditions.

The results of above studies with 125 mg formulations can be extrapolated to the other strength 80 mg.

IV.3 Pharmacodynamics

Clinical pharmacology studies to evaluate the pharmacodynamics of Aprepitant Sandoz 80 mg and 125 mg hard capsules were not performed.

IV.4 Clinical efficacy

No new efficacy data have been submitted and none are required. The applicant has provided an adequate literature review to describe the efficacy profile of aprepitant.

IV.5 Clinical safety

With the exception of the data generated during the bioequivalence studies, no new safety data were submitted, and none were required for this application. No new or unexpected safety issues were raised by the bioequivalence data.

The applicant has provided an adequate literature review to describe the safety profile of aprepitant.

IV.6 Pharmacovigilance

IV.6.1 Summary of the Pharmacovigilance System

The applicant has submitted a signed Summary of the Applicant's Pharmacovigilance System. Provided that the Pharmacovigilance System Master File fully complies with the new legal requirements as set out in the Commission Implementing Regulation 520/2012 and as detailed in the relevant Good Pharmacovigilance Practice module, the Summary is considered acceptable.

IV.6.2 Risk Management Plan

<i>Summary of safety concerns</i>	
Important identified risks	Hypersensitivity.
	Drug interaction: hormonal contraceptives.
Important potential risks	Potential for medication errors.
Missing information	Use in pregnancy.
	Use in children less than 12 years of age.
	Use in patients with moderate or severe hepatic impairment.

Pharmacovigilance Plan: routine pharmacovigilance activities are considered sufficient to manage all of the safety concerns connected to Aprepitant Sandoz 80 mg, 125 mg hard capsule and 125 mg + 80 mg hard capsules. No additional activities are proposed.

Risk Minimisation Measures: routine measures (i.e. wording in the Summary of Product Characteristics, Package Leaflet and classification as a prescription only-medicine) are considered sufficient to manage all of the safety concerns connected to Aprepitant Sandoz 80 mg, 125 mg hard capsule and 125 mg+ 80 mg hard capsules. No additional activities are proposed. For any further information on risk minimisation, please refer to the product information.

IV.6.3 Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for these medicinal products are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

IV.7 Discussion on the clinical aspects

The application concerns a generic product.

Abridged applications avoid the need for repetitive tests on animals and humans. For these applications, the bioequivalence studies described in section IV.2 are pivotal.

Based on the submitted bioequivalence studies the single dose of the applicant's aprepitant capsules 125 mg and Emend® 125 mg capsules (125 mg aprepitant) (Merck Sharp & Dohme Ltd., UK) are bioequivalent in healthy adult human subjects under fasting and fed conditions. This can be extrapolated to the other strength 80 mg.

There is no objection against granting the marketing authorization from a clinical point of view.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

V.1 Summary

The present applications concern Aprepitant Sandoz 80 mg, 125 mg and 125 mg + 80 mg hard capsules, generic versions of aprepitant. The applicant and the future holder of authorisation is Sandoz Hungária Kft. in the RMS.

Aprepitant Sandoz is indicated for prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.

The application was submitted according to Article 10(1) of Directive 2001/83/EC (generic application). The reference product was Emend[®] capsule (Merck Sharp & Dohme Ltd.) The applicant demonstrated bioequivalence of the 125 mg strengths of Test and Reference products that could be extended to the 80 mg strength according to the bioequivalence guideline (*CPMP/EWP/QWP/1401/98/rev 1/Corr***).

The submitted documentation is administratively adequate and scientifically sound. The quality of the product is satisfactory. There were no non-clinical or clinical concerns raised.

The therapeutic benefit/risk assessment is, therefore, positive.

Based on the review of the quality, safety and efficacy data, the Member States have granted marketing authorisation for Aprepitant Sandoz 80 mg, 125 mg and 125 mg + 80 mg hard capsules.

V.2 Classification

Prescription-only medicine.

V.3 Package Leaflet and user consultation

The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The language used for the purpose of user testing the patient information leaflet was English.

The results show that the package leaflet meets the criteria for readability as set out in the *Guideline on the readability of the label and package leaflet of medicinal products for human use*.

National Institute of Pharmacy
and Nutrition
Budapest, Hungary

Aprepitant Sandoz
80 mg, 125 mg, 125 mg + 80 mg hard capsules
HU/H/0498/001-003/DC
Public Assessment Report

VI. Upgrade: steps taken after the initial procedure with an influence on the Public Assessment Report

This module reflects the procedural steps and scientific information after the finalisation of the initial procedure.

Scope	Procedure number	Product information affected	Date of start of the procedure	Date of end of procedure	Approval or non approval	Assessment report attached
Repeat-use procedure relating the 125 mg + 80 mg 3-day treatment pack, involving Croatia as CMS	HU/H/0498/003/E/001	yes	28. 06. 2018	27. 08. 2018	approval	no
Repeat-use procedure relating the 125 mg + 80 mg 3-day treatment pack, involving Spain as CMS	HU/H/0498/003/E/002	yes	22, 08. 2019	21. 10. 2019	approval	no
IB C.I.1.1.z Submission of the new version of the Risk-Management Plan	HU/H/0498/001-003/002	no	21. 02. 2020	26, 03, 2020	approval	no